RPRX – Royalty Pharma plc
RPRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.35
Margin Of Safety %
-19
Put/Call OI Ratio
0.21
EPS Next Q Diff
0.6
EPS Last/This Y
3.33
EPS This/Next Y
0.5
Price
53.06
Target Price
59.57
Analyst Recom
1.5
Performance Q
17.62
Upside
-20.8%
Beta
0.4
Ticker: RPRX
21 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-21 | RPRX | 49.49 | 0.23 | 0.36 | 8988 |
| 2026-04-23 | RPRX | 49.65 | 0.23 | 3.00 | 9046 |
| 2026-04-24 | RPRX | 49.38 | 0.23 | 0.00 | 9049 |
| 2026-04-27 | RPRX | 49.65 | 0.23 | 0.36 | 9054 |
| 2026-04-28 | RPRX | 49.54 | 0.23 | 0.00 | 9087 |
| 2026-04-29 | RPRX | 49.49 | 0.23 | 0.00 | 9078 |
| 2026-04-30 | RPRX | 50.1 | 0.23 | 0.11 | 9078 |
| 2026-05-01 | RPRX | 49.45 | 0.23 | 0.00 | 9067 |
| 2026-05-04 | RPRX | 50.19 | 0.23 | 0.06 | 9076 |
| 2026-05-05 | RPRX | 50.47 | 0.23 | 0.00 | 9084 |
| 2026-05-06 | RPRX | 50.7 | 0.22 | 0.15 | 9361 |
| 2026-05-07 | RPRX | 50.2 | 0.22 | 0.58 | 9371 |
| 2026-05-08 | RPRX | 50.81 | 0.23 | 0.09 | 9521 |
| 2026-05-11 | RPRX | 51.64 | 0.23 | 0.00 | 9646 |
| 2026-05-12 | RPRX | 51.69 | 0.18 | 0.00 | 11460 |
| 2026-05-13 | RPRX | 53.27 | 0.18 | 0.00 | 11540 |
| 2026-05-14 | RPRX | 53.37 | 0.19 | 0.00 | 11213 |
| 2026-05-15 | RPRX | 52.82 | 0.20 | 0.00 | 10727 |
| 2026-05-18 | RPRX | 52.06 | 0.21 | 0.00 | 10014 |
| 2026-05-19 | RPRX | 52.4 | 0.21 | 0.01 | 10015 |
| 2026-05-20 | RPRX | 53.06 | 0.21 | 0.00 | 9903 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
21 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-21 | RPRX | 49.49 | 14.7 | 137.3 | 5.10 |
| 2026-04-22 | RPRX | 49.71 | 14.7 | 138.2 | 5.10 |
| 2026-04-23 | RPRX | 49.63 | 14.7 | 130.0 | 5.10 |
| 2026-04-24 | RPRX | 49.38 | 12.1 | 125.3 | 5.10 |
| 2026-04-27 | RPRX | 49.65 | 12.1 | 139.3 | 5.10 |
| 2026-04-28 | RPRX | 49.54 | 12.1 | 129.2 | 5.10 |
| 2026-04-30 | RPRX | 50.10 | 12.1 | 148.2 | 5.10 |
| 2026-05-01 | RPRX | 49.45 | 12.1 | 115.0 | 5.10 |
| 2026-05-04 | RPRX | 50.20 | 12.1 | 152.4 | 5.10 |
| 2026-05-05 | RPRX | 50.47 | 12.1 | 139.1 | 5.10 |
| 2026-05-06 | RPRX | 50.68 | 12.1 | 137.7 | 5.10 |
| 2026-05-07 | RPRX | 50.21 | 12.1 | 112.4 | 5.10 |
| 2026-05-08 | RPRX | 50.80 | 12.1 | 85.6 | 5.08 |
| 2026-05-11 | RPRX | 51.64 | 12.0 | -169.3 | 5.08 |
| 2026-05-12 | RPRX | 51.69 | 11.8 | -187.1 | 5.12 |
| 2026-05-13 | RPRX | 53.25 | 11.8 | -154.0 | 5.12 |
| 2026-05-14 | RPRX | 53.37 | 11.8 | -185.8 | 5.12 |
| 2026-05-15 | RPRX | 52.81 | 11.8 | -195.2 | 5.12 |
| 2026-05-18 | RPRX | 52.07 | 11.8 | -200.1 | 5.12 |
| 2026-05-19 | RPRX | 52.40 | 11.8 | -175.8 | 5.12 |
| 2026-05-20 | RPRX | 53.06 | 11.8 | -174.0 | 5.12 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
21 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-21 | RPRX | -3.19 | 3.85 | 2.90 |
| 2026-04-22 | RPRX | -3.19 | 3.85 | 2.90 |
| 2026-04-23 | RPRX | -3.21 | 3.85 | 2.90 |
| 2026-04-24 | RPRX | -3.21 | 3.85 | 2.90 |
| 2026-04-27 | RPRX | -3.13 | 3.54 | 2.92 |
| 2026-04-28 | RPRX | -3.13 | 3.54 | 2.92 |
| 2026-04-29 | RPRX | -3.21 | 3.54 | 2.92 |
| 2026-04-30 | RPRX | -3.21 | 3.54 | 2.92 |
| 2026-05-01 | RPRX | -3.29 | 3.54 | 2.92 |
| 2026-05-04 | RPRX | -3.29 | 3.30 | 2.92 |
| 2026-05-05 | RPRX | -3.29 | 3.30 | 2.92 |
| 2026-05-06 | RPRX | -3.29 | 3.30 | 2.92 |
| 2026-05-07 | RPRX | -3.29 | 3.30 | 2.92 |
| 2026-05-08 | RPRX | -3.29 | 3.30 | 2.92 |
| 2026-05-11 | RPRX | -3.29 | 4.00 | 2.92 |
| 2026-05-12 | RPRX | -3.30 | 4.00 | 3.35 |
| 2026-05-13 | RPRX | -3.30 | 4.00 | 3.35 |
| 2026-05-14 | RPRX | -3.30 | 4.00 | 3.35 |
| 2026-05-15 | RPRX | -3.30 | 4.00 | 3.36 |
| 2026-05-18 | RPRX | -3.34 | 3.97 | 3.35 |
| 2026-05-19 | RPRX | -3.43 | 3.97 | 3.35 |
| 2026-05-20 | RPRX | -3.28 | 3.97 | 3.35 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
22 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
0.53
Avg. EPS Est. Current Quarter
1.27
Avg. EPS Est. Next Quarter
1.13
Insider Transactions
-3.28
Institutional Transactions
3.97
Beta
0.4
Average Sales Estimate Current Quarter
805
Average Sales Estimate Next Quarter
872
Fair Value
43.21
Quality Score
64
Growth Score
69
Sentiment Score
93
Actual DrawDown %
0.8
Max Drawdown 5-Year %
-43.4
Target Price
59.57
P/E
27.79
Forward P/E
9.44
PEG
1.03
P/S
12.52
P/B
3.42
P/Free Cash Flow
11.22
EPS
1.91
Average EPS Est. Cur. Y
5.12
EPS Next Y. (Est.)
5.61
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
33.89
Relative Volume
0.85
Return on Equity vs Sector %
-15
Return on Equity vs Industry %
0.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.06
EBIT Estimation
-174
◆
RPRX
Healthcare
$53.06
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
20/20
Pullback
6/25
Volume
7/15
Valuation
7/20
TP/AR
4/10
Options
7/10
RSI
67.8
Range 1M
95.2%
Sup Dist
2.1%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
14/25
Growth
14/30
Estimates
6/20
Inst/Vol
7/15
Options
8/10
EPS Yr
6.2%
EPS NY
9.6%
52W%
99%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+63.2% upside
Quality
6/30
Valuation
16/30
Growth
9/25
Stability
6/10
LT Trend
4/5
Upside
+63.2%
Quality
64
MoS
-19%
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 100
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
RPRX
Latest News
—
Caricamento notizie per RPRX…
stock quote shares RPRX – Royalty Pharma plc Stock Price stock today
news today RPRX – Royalty Pharma plc stock forecast ,stock prediction 2023 2024 2025
marketwatch RPRX – Royalty Pharma plc yahoo finance google finance
stock history RPRX – Royalty Pharma plc invest stock market
stock prices RPRX premarket after hours
ticker RPRX fair value insiders trading